← Back to Oxyglobin / HBOC-301 evidence overview
EMA Approval - Oxyglobin (EU/2/99/015)
Field-Trial Treatment Success
The percentages below are treatment-success rates, not the frequency or severity of each cause of anaemia. Success was defined as no need for additional oxygen-carrying support during the 24-hour efficacy window; it was not a survival endpoint.
Treatment success by cause of anaemia
Haemolytic anaemia
Anaemia from ineffective erythropoiesis
How to read “100%”: all evaluable Oxyglobin-treated dogs in that cause-of-anaemia stratum met the 24-hour treatment-success endpoint. It does not mean “100% ineffective erythropoiesis” or “100% haemolysis,” and it is not a 100% survival or cure claim.
EMA Oxyglobin EPAR / Scientific Discussion ↗ · FDA FOI field-trial endpoint and denominators ↗
Overview
| Parameter | Detail |
|---|---|
| Registration Number | EU/2/99/015 |
| Approval Date | 29 November 1999 |
| Decision Number | C(1999)3846 |
| Sponsor | Biopure Corporation |
| Product Name | Oxyglobin |
| Active Substance | haemoglobin glutamer-200 (bovine) |
| EMA Product Number | EMEA/V/C/000045 |
| Species | Dogs |
European Veterinary Approval
The European Commission granted the original marketing authorisation on 29 November 1999, under Decision C(1999)3846 and Community registration EU/2/99/015.
Official Records
- EMA Oxyglobin regulatory record
- Original 1999 European Commission Annexes
- 2001 European Commission Annexes - archived repository copy (18 December)
- 2001 European Commission Annexes - verify at official EC source
- 2021 European Commission authorisation amendment (18 October)
2001 Revised Product Information
The European Commission annexes dated 18 December 2001 provide a primary regulatory source for Oxyglobin 130 mg/mL solution for infusion in dogs. They state that Oxyglobin is a haemoglobin-based oxygen-carrying fluid, identify haemoglobin glutamer-200 (bovine) at 130 mg/mL, and document the product-specific pharmacokinetic, compatibility and storage information summarized below.
Open the archived 2001 European Commission Annexes ↗ · Verify at the official European Commission source ↗
Original Annexes
| Annex | Content |
|---|---|
| Annex I | Summary of Product Characteristics (SmPC) |
| Annex II | Conditions of the Marketing Authorisation |
| Annex III | Labelling and Package Insert |
Presentations
| Version | Presentation |
|---|---|
| Original (1999) | Box containing two separately wrapped 125 mL bags |
| Subsequent presentations (see current EMA product information) | Individual 60 mL and 125 mL presentations |
Therapeutic Indication
Oxyglobin provides oxygen-carrying support to dogs and improves clinical signs of anemia for at least 24 hours, independent of the underlying condition.
"Oxyglobin provides oxygen-carrying support to dogs for at least 24 hours." - EMA Assessment Report
Pharmacokinetics
| Parameter | Detail |
|---|---|
| Plasma Half-life | Approximately 30-40 hours |
| Complete Elimination | 5-7 days |
| Transient Hemoglobinuria | <4 hours (<5% tetramer fraction) |
Safety & Contraindications
| Parameter | Detail |
|---|---|
| Volume Expansion | Dual oxygen-carrying and colloid effects |
| Contraindications | Dogs at risk of circulatory overload (advanced cardiac disease, severely impaired cardiac function, renal impairment with oliguria/anuria) |
| Monitoring | Signs of circulatory overload or CVP measurement |
| Pregnancy/Lactation | Safety not determined; use not recommended |
Storage & Stability
| Parameter | Detail |
|---|---|
| Storage Condition | Do not store above 30°C |
| Shelf Life | 3 years (documented in the 18 December 2001 European Commission Annexes) |
| Do Not Freeze | Yes |
Sources
EMA Oxyglobin EPAR, European Commission primary documents for Oxyglobin (EU/2/99/015), and the FDA field-trial record where the endpoint and population denominators are explicit.
Open the Oxyglobin EU regulatory chronology →
Last updated: 16 September 2026